Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells

Cancer Research

Volumn 60, Issue 20, 2000, Pages 5887-5894

  Kurokawa, Hirokazu ^a   Lenferink, Anne E G ^a   Simpson, Jean F ^a   Pisacane, Paul I ^c   Sliwkowski, Mark X ^c   Forbes, James T ^a   Arteaga, Carlos L ^a,b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT INGRAM CANCER CENTER   (United States)

^c GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; TAMOXIFEN;

ARTICLE; BREAST CANCER; ENZYME INHIBITION; GENE EXPRESSION; HUMAN; HUMAN CELL; ONCOGENE NEU; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANIMALS; BREAST NEOPLASMS; BUTADIENES; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; ESTROGEN RECEPTOR MODULATORS; FEMALE; GENE EXPRESSION; HUMANS; MAP KINASE SIGNALING SYSTEM; MICE; MICE, NUDE; MITOGEN-ACTIVATED PROTEIN KINASES; NITRILES; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; TAMOXIFEN; TRANSCRIPTION, GENETIC; TYRPHOSTINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0034667395     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Tamoxifen resistance in breast cancer
2. Acquired estrogen independence and antiestrogen resistance in breast cancer-estrogen receptor driven phenotypes?
3. Tamoxifen resistant breast cancer: Coregulators determine the direction of transcription by antagonist-occupied steroid receptors
4. The ErbB-2/HER2 oncogenic receptor of adenocarcinomas: From orphanhood to multiple stromal ligands
5. Specificity within the EGF family/ErbB receptor family signaling network
6. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu
7. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells
8. MCF-7 breast cancer cells overexpressing transfected c-erbB-2 have an in vitro growth advantage in estrogen-depleted conditions and reduced estrogen-dependence and tamoxifen-sensitivity in vivo
9. Epidermal growth factor receptors in breast cancer: Association with early relapse and death, poor response to hormones and interactions with neu
10. Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer
11. ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer
12. Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer
13. c-erbB2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases
14. Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein
15. Oncogene amplification and prognosis in breast cancer: Relationship with systemic treatment
16. Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy
17. Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer
18. HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: A Southwest Oncology Group Study
19. HER-2/neu and p53 expression vs tamoxifen resistance in estrogen-receptor-positive, node-positive breast cancer
20. Activation of the Ras signalling pathway in human breast cancer cells overexpressing erbB-2
21. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase
22. Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation
23. Enhanced anti-proliferative activity of the combination of tamoxifen plus HER-2-neu antibody
24. Tamoxifen-resistant fibroblast growth factor-transfected MCF-7 cells are cross-resistant in vivo to the antiestrogen IC1 182,780 and two aromatase inhibitors
25. Mitogen-activated protein kinase kinase 2 activation is essential for progression through the G2/M checkpoint arrest in cells exposed to ionizing radiation
26. Proteasome-dependent degradation of the human estrogen receptor
27. Unliganded epidermal growth factor receptor dimerization induced by direct interaction of quinazolines with the ATP binding site
28. Identification of a novel inhibitor of mitogen-activated protein kinase kinase
29. Real time quantitative PCR
30. A novel method for real time quantitative RT-PCR
31. Biologic effects of heregulin/neu differentiation factor on normal and malignant human breast and ovarian epithelial cells
32. The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N-CoR or SMRT
33. Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas
34. Emergence of MCF-7 cells overexpressing a transfected epidermal growth factor receptor (EGFR) under estrogen-depleted conditions: Evidence for a role of EGFR in breast cancer growth and progression
35. Ectopic expression of epidermal growth factor receptors induces hormone independence in ZR-75-1 human breast cancer cells
36. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling
37. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model
38. Increased MAPK activity in EGFR erbB-2 overexpressing MCF-7 cells induces down-regulation of estrogen receptor (ER) expression
39. Inhibition of mitogen-activated protein kinase and phosphatidylinositol 3-kinase activity in MCF-7 cells prevents estrogen-induced mitogenesis
40. Modulation of transcription activation by ligand-dependent phosphorylation of the human oestrogen receptor A/B region
41. pp90(rsk1) regulates estrogen receptor-mediated transcription through phosphorylation of Ser-167
42. Estradiol-induced phosphorylation of serine 118 in the estrogen receptor is independent of p42/p44 mitogen-activate protein kinase
43. Anti-HER2 antibody enhance the growth inhibitory effect of anti-oestrogen on breast cancer cells expressing both oestrogen receptors and HER2
44. Alteration in the agonist/antagonist balance of antiestrogens by activation of protein kinase A signaling pathways in breast cancer cells: Antiestrogen selectivity and promoter dependence
45. Modulation of the ligand-independent activation of the human estrogen receptor by hormone and antihormone
46. Diverse signaling pathway modulate nuclear receptor recruitment of N-CoR and SMRT complexes